In the last decades, the prognosis of metastatic renal cell carcinoma (mRCC) has
remarkably improved following the advent of the “targeted therapy” era. The expanding …

Background Identification of high-risk localised renal cell carcinoma is key for the selection
of patients for adjuvant treatment who are at truly higher risk of reccurrence. We developed a …

Background Exploration on genetic roles in antineoplastic-related cardiovascular toxicity
has increased with the advancement of genotyping technology. However, knowledge on the …

Molecular markers of sorafenib efficacy in patients with metastatic renal cell carcinoma
(mRCC) are not available. The purpose of this study was to discover genetic markers of …

Abstract Purpose: In the S-TRAC trial, adjuvant sunitinib prolonged disease-free survival
(DFS) versus placebo in patients with loco-regional renal cell carcinoma at high risk of …

Aim: Evaluate associations between clinical outcomes and SNPs in patients with well-
differentiated pancreatic neuroendocrine tumors receiving sunitinib. Patients & methods …

Background and aim: Vascular endothelial growth factor receptor tyrosine kinase inhibitors
(VEGFR-TKIs) cause significant adverse events including thyroid dysfunction, mainly …

Abstract Background Long-term responders (LTRs) are defined by at least 18 months of
response to sunitinib in metastatic clear-cell renal cell carcinoma (ccRCC). Well-described …

Background There are no validated markers that predict response or resistance in patients
with metastatic clear-cell renal cell carcinoma (mccRCC) treated with vascular endothelial …

From 2007 to 2011, the adjuvant sunitinib in high-risk renal cell carcinoma (RCC) after
nephrectomy (S-TRAC) investigators conducted a phase 3, randomized, placebocontrolled …